TORONTO--(BUSINESS WIRE)--Dec. 21, 2005--Biovail Corporation (NYSE:BVF)(TSX:BVF) announced today that it has received an Approval Letter from the United States Food and Drug Administration (FDA) for its New Drug Application for an orally disintegrating tablet formulation of citalopram hydrobromide (HBr) for the treatment of depression. Biovail believes that its novel formulation of citalopram HBr, may offer physicians a new dosing option with potential benefits and prescribing flexibility that may be advantageous when addressing the needs of certain patients.